Bildkälla: Stockfoto

Alzinova: New Encouraging Interim Data From Phase Ib Study - Redeye

Redeye comments on the new positive data from the second interim analysis of the ongoing phase Ib study with Alzinova’s vaccine candidate ALZ-101.

Redeye comments on the new positive data from the second interim analysis of the ongoing phase Ib study with Alzinova’s vaccine candidate ALZ-101.
Börsvärldens nyhetsbrev
ANNONSER